Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,573.78
(
-0.77%
)
US TECH 100
23,602.00
(
-0.82%
)
Dow Jones
45,816.87
(
-0.88%
)
Brent Oil
105.74
(
-0.79%
)
Bitcoin
69,567.90
(
-2.35%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122799
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 96184

Friday, 05/21/2010 7:46:55 PM

Friday, May 21, 2010 7:46:55 PM

Post# of 257259
ANDS: I’m with you—i.e. skeptical of the company’s assertion that ANA598 is one of the most attractive drug candidates in the HCV arena. To the contrary, ANA598 strikes me as a drug with a narrow therapeutic window (#msg-47087879), and it appears to be inferior to, among others, VX-222, the non-nuke from VRTX.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now